Chemed Corp (CHE) stock
CHENYSEServices-Home Health Care ServicesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 17/305% above fair value
$550.62+6.13 (+1.13%)
Close on Nov 11, 2026Market cap $7.17BP/E 26.3Yield 0.40%
Chemed EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
Chemed's EPS for the twelve months ending Sep 30, 2026 was $20.91, up 10.5% year over year. For fiscal 2025 it was $18.34, down 7.8% from the year before. Over ten years it grew 11.2% a year on average. The highest annual figure on record is $19.89 in fiscal 2024.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $18.34 | -7.8% |
| FY2024 | Dec 31, 2024 | $19.89 | +10.9% |
| FY2023 | Dec 31, 2023 | $17.93 | +8.5% |
| FY2022 | Dec 31, 2022 | $16.53 | -1.9% |
| FY2021 | Dec 31, 2021 | $16.85 | -13.5% |
| FY2020 | Dec 31, 2020 | $19.48 | +46.4% |
| FY2019 | Dec 31, 2019 | $13.31 | +8.8% |
| FY2018 | Dec 31, 2018 | $12.23 | +108.7% |
| FY2017 | Dec 31, 2017 | $5.86 | -9.6% |
| FY2016 | Dec 31, 2016 | $6.48 | +2.4% |
| FY2015 | Dec 31, 2015 | $6.33 | +13.6% |
| FY2014 | Dec 31, 2014 | $5.57 | +33.9% |
| FY2013 | Dec 31, 2013 | $4.16 | -10.0% |
| FY2012 | Dec 31, 2012 | $4.62 | +12.7% |
| FY2011 | Dec 31, 2011 | $4.10 | +15.5% |
| FY2010 | Dec 31, 2010 | $3.55 | +9.6% |
| FY2009 | Dec 31, 2009 | $3.24 | +12.5% |
| FY2008 | Dec 31, 2008 | $2.88 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $5.45 | +22.2% |
| Q2 FY2026 | Jun 30, 2026 | $5.13 | +43.7% |
| Q1 FY2026 | Mar 31, 2026 | $4.84 | -0.4% |
| Q4 FY2025 | Dec 31, 2025 | $5.49 | -9.0% |
| Q3 FY2025 | Sep 30, 2025 | $4.46 | -10.8% |
| Q2 FY2025 | Jun 30, 2025 | $3.57 | -23.2% |
| Q1 FY2025 | Mar 31, 2025 | $4.86 | +14.6% |
| Q4 FY2024 | Dec 31, 2024 | $6.03 | +2.2% |
| Q3 FY2024 | Sep 30, 2024 | $5.00 | +1.4% |
| Q2 FY2024 | Jun 30, 2024 | $4.65 | +32.5% |
| Q1 FY2024 | Mar 31, 2024 | $4.24 | +18.4% |
| Q4 FY2023 | Dec 31, 2023 | $5.90 | +42.9% |
| Q3 FY2023 | Sep 30, 2023 | $4.93 | +30.4% |
| Q2 FY2023 | Jun 30, 2023 | $3.51 | -20.2% |
| Q1 FY2023 | Mar 31, 2023 | $3.58 | -15.2% |
| Q4 FY2022 | Dec 31, 2022 | $4.13 | -14.1% |
| Q3 FY2022 | Sep 30, 2022 | $3.78 | -16.9% |
| Q2 FY2022 | Jun 30, 2022 | $4.40 | +25.4% |
| Q1 FY2022 | Mar 31, 2022 | $4.22 | +5.2% |
| Q4 FY2021 | Dec 31, 2021 | $4.81 | -30.9% |
| Q3 FY2021 | Sep 30, 2021 | $4.55 | +9.9% |
| Q2 FY2021 | Jun 30, 2021 | $3.51 | -29.9% |
| Q1 FY2021 | Mar 31, 2021 | $4.01 | +18.6% |
| Q4 FY2020 | Dec 31, 2020 | $6.96 | +75.8% |
| Q3 FY2020 | Sep 30, 2020 | $4.14 | +16.3% |
| Q2 FY2020 | Jun 30, 2020 | $5.01 | +62.7% |
| Q1 FY2020 | Mar 31, 2020 | $3.38 | +25.2% |
| Q4 FY2019 | Dec 31, 2019 | $3.96 | +21.8% |
| Q3 FY2019 | Sep 30, 2019 | $3.56 | +16.3% |
| Q2 FY2019 | Jun 30, 2019 | $3.08 | -5.8% |
| Q1 FY2019 | Mar 31, 2019 | $2.70 | +1.5% |
| Q4 FY2018 | Dec 31, 2018 | $3.25 | -0.6% |
| Q3 FY2018 | Sep 30, 2018 | $3.06 | +43.7% |
| Q2 FY2018 | Jun 30, 2018 | $3.27 | – |
| Q1 FY2018 | Mar 31, 2018 | $2.66 | +49.4% |
| Q4 FY2017 | Dec 31, 2017 | $3.27 | +68.6% |
| Q3 FY2017 | Sep 30, 2017 | $2.13 | – |
| Q2 FY2017 | Jun 30, 2017 | -$1.35 | – |
| Q1 FY2017 | Mar 31, 2017 | $1.78 | – |
| Q4 FY2016 | Dec 31, 2016 | $1.94 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?